Abstract:Introduction Consensus Molecular Subtypes (CMS) represent a well-established molecular stratification framework for colorectal cancer (CRC). Existing methods for CMS classification rely on a representative input cohort as a preprocessing step (CMScaller) or have difficulty generalizing to metastatic samples (CMSclassifier). We developed Tempus CMS to overcome these limitations. Our method normalizes gene expression data from input samples to a static reference cohort to enable single sample classification of both primary and metastatic tumors. We evaluated the performance of this classifier on a large, de-identified CRC cohort comprising 8,489 samples from primary and metastatic sites. Methods To normalize input data, our method shifts and scales each gene expression value based on the mean and standard deviation of the expression of that gene in the reference cohort (n=2,787 primary and metastatic CRC). CMS calls are then generated via nearest template prediction similar to CMScaller (Eide et al., 2017). The analysis cohort was selected from clinical biopsies within 30 days of primary or metastatic diagnosis excluding reference cohort samples. CMS calls were assessed by comparing subtype prevalence to reported rates and by testing for known enrichments of pathways and genomic markers. Results Subtype prevalences for lower gastrointestinal (GI) biopsies and resections (n=5,090) were comparable to reported rates for primary CRC tumors: CMS1 - 12%, CMS2 - 28%, CMS3 - 19%, and CMS4 - 33% with 7.6% no calls. Biopsies from metastatic tissue showed site-specific changes in prevalence: CMS2 increased to 43% in liver samples (n=1,715) and CMS4 was identified in 49% of samples from metastatic sites excluding the liver (n=1,684). In addition, we found that purity had an effect on prevalence: in lower GI tumors with ≥ 50% tumor purity rates of CMS2 and CMS4 were 34% and 26%, respectively, while rates in tumors with purity between 20% and 50% were 20% CMS2 and 41% CMS4. Across all tissue groups, pathway enrichment showed significant associations, including TGF-ꞵ signaling in CMS4 (adj P ≤ 4.4e-15) and cell differentiation in CMS3 (adj P ≤ 3.0e-27). Expected enrichments of CMS markers were also observed: BRAF mutations and microsatellite instability in CMS1 and KRAS mutations in CMS3. In liver tissue, higher KRAS mutation rates were noted in CMS1 (57%) and CMS3 (83%) compared to GI tissue (35% and 67%, respectively). Conclusions In this study, we developed an enhanced, single sample CMS-calling algorithm optimized for primary and metastatic sites. Application of this algorithm in a large cohort recapitulated known biology, which suggests that the tool can be used to support clinical studies requiring robust molecular stratification. Citation Format: Andrew J. Sedgewick, Tushar Chandra, Timothy Taxter, Justin Guinney. Robust single sample consensus molecular subtype classification for primary and metastatic colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5059.

Refining colorectal cancer classification and clinical stratification through a single-cell atlas

Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer

Comprehensive characterization of tumor microenvironment in colorectal cancer via molecular analysis

Colorectal Cancer Stem Cell Subtypes Orchestrate Distinct Tumor Microenvironments

Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics

A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues

From Subtypes to Solutions: Integrating CMS Classification with Precision Therapeutics in Colorectal Cancer

The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer

The consensus molecular subtypes of colorectal cancer

Abstract 5059: Robust single sample consensus molecular subtype classification for primary and metastatic colorectal cancer

Molecular subtypes of colorectal cancer in the era of precision oncotherapy: Current inspirations and future challenges

Single-cell chromatin accessibility analysis reveals the epigenetic basis and signature transcription factors for the molecular subtypes of colorectal cancers

Abstract 409: Deciphering chromosomal instability in consensus molecular subtypes (CMS) in CRC: Insights from an integrative multi-omics approach

Correction: A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues

Integration of single-cell RNA sequencing and bulk RNA transcriptome sequencing reveals a heterogeneous immune landscape and pivotal cell subpopulations associated with colorectal cancer prognosis

Multiregion single‐cell sequencing reveals the transcriptional landscape of the immune microenvironment of colorectal cancer

Single cell dynamics of tumor specificity vs bystander activity in CD8+ T cells define the diverse immune landscapes in colorectal cancer

Single-cell transcriptome analysis reveals heterogeneity and convergence of the tumor microenvironment in colorectal cancer

Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors

Single-cell Multiomics Sequencing and Analyses of Human Colorectal Cancer

Integrated multi-omics characterization of KRAS mutant colorectal cancer